Pear Therapeutics and BrightView Health have expanded a pilot program providing prescription digital therapeutics for substance use disorders.
The expansion means that Pear's (NASDAQ:PEAR) reSET and reSET-O therapeutics are now available to BrightView patients in Kentucky, Ohio, Delaware, Massachusetts, and Virginia.
ReSET is a monotherapy for patients 18 years of age or older with substance use disorder, while reSET-O is used in combination with buprenorphine for opioid use disorder.